Skip to main content
Premium Trial:

Request an Annual Quote

More Doors Close, But a Crack of Light Gets Through

Two Massachusetts-based biotech companies folded this week, reports the Boston Globe. Epix Pharmaceuticals is undergoing liquidation, and Biopure has filed for Chapter 11. The Wall Street Journal's Health Blog says that not all biotechs are in trouble, adding that analysts say companies with promising late-stage compounds or products on the market are likely to have less trouble. Shocking.

The Cross-Border Biotech Blog, however, has a more optimistic post today, saying that there may be more incentives for funding biotechs. Jeremy Grushcow points to Human Genome Sciences' last report that surprised analysts and to a MoneyTree report from the National Venture Capital Association and PricewaterhouseCooper finding that, in the second quarter of this year, biotech was the biggest recipient of venture funds with $3.67 billion.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.